1. Home
  2. CGTX vs CATO Comparison

CGTX vs CATO Comparison

Compare CGTX & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • CATO
  • Stock Information
  • Founded
  • CGTX 2007
  • CATO 1946
  • Country
  • CGTX United States
  • CATO United States
  • Employees
  • CGTX N/A
  • CATO N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • CATO Clothing/Shoe/Accessory Stores
  • Sector
  • CGTX Health Care
  • CATO Consumer Discretionary
  • Exchange
  • CGTX Nasdaq
  • CATO Nasdaq
  • Market Cap
  • CGTX 53.4M
  • CATO 57.6M
  • IPO Year
  • CGTX 2021
  • CATO N/A
  • Fundamental
  • Price
  • CGTX $2.41
  • CATO $4.72
  • Analyst Decision
  • CGTX Strong Buy
  • CATO
  • Analyst Count
  • CGTX 3
  • CATO 0
  • Target Price
  • CGTX $2.83
  • CATO N/A
  • AVG Volume (30 Days)
  • CGTX 12.4M
  • CATO 197.8K
  • Earning Date
  • CGTX 08-07-2025
  • CATO 08-21-2025
  • Dividend Yield
  • CGTX N/A
  • CATO 3.59%
  • EPS Growth
  • CGTX N/A
  • CATO N/A
  • EPS
  • CGTX N/A
  • CATO N/A
  • Revenue
  • CGTX N/A
  • CATO $650,830,000.00
  • Revenue This Year
  • CGTX N/A
  • CATO N/A
  • Revenue Next Year
  • CGTX N/A
  • CATO N/A
  • P/E Ratio
  • CGTX N/A
  • CATO N/A
  • Revenue Growth
  • CGTX N/A
  • CATO N/A
  • 52 Week Low
  • CGTX $0.22
  • CATO $2.19
  • 52 Week High
  • CGTX $3.83
  • CATO $6.70
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 61.15
  • CATO 76.76
  • Support Level
  • CGTX $2.26
  • CATO $3.84
  • Resistance Level
  • CGTX $2.67
  • CATO $4.55
  • Average True Range (ATR)
  • CGTX 0.40
  • CATO 0.30
  • MACD
  • CGTX -0.03
  • CATO 0.10
  • Stochastic Oscillator
  • CGTX 42.08
  • CATO 90.95

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

Share on Social Networks: